Ursodeoxycholic Acid: Hydrophilic Bile Acid
Ursodeoxycholic acid (UDCA) is a naturally occurring secondary bile acid that constitutes a minor fraction of the human bile acid pool. Its mechanism involves replacing more hydrophobic, cytotoxic bile acids in the bile pool through competitive displacement, reducing cholesterol saturation of bile, and exerting cytoprotective effects on hepatocyte membranes. UDCA also has immunomodulatory properties, reducing HLA class I antigen expression on hepatocytes.
Product Profile
| CAS Number | 128-13-2 |
|---|---|
| Molecular Formula | C24H40O4 |
| Appearance | White crystalline powder, bitter taste |
| Therapeutic Category | Bile acid / hepatoprotective |
| Storage | Room temperature, dry conditions |
Applications
UDCA is the standard medical treatment for primary biliary cholangitis (PBC), where it slows disease progression and improves liver biochemistry. It is also used for dissolution of small, radiolucent gallstones in patients who are not candidates for cholecystectomy. In cystic fibrosis-related liver disease, UDCA is prescribed to improve bile flow. Typical oral dosing is 13–15 mg/kg/day in divided doses. UDCA is formulated as tablets and capsules and is also used in veterinary hepatology for chronic hepatitis in dogs.
Why Source from TCS
TCS supplies ursodeoxycholic acid to pharmaceutical companies across Europe and globally. Flexible order quantities from development samples to commercial volumes. Contact us with your target market and project requirements for a tailored quotation.
FAQ
What information should be included in an inquiry for Ursodeoxycholic Acid 128-13-2?
A useful inquiry normally includes the product name, target application, estimated quantity, destination market, and any specific documentation or packaging requests.
How is Ursodeoxycholic Acid 128-13-2 usually evaluated for sourcing?
This product is positioned for pharmaceutical sourcing discussions covering development, pilot, or commercial demand, subject to the buyer confirming application scope, market, and document requirements.
What documentation and commercial points are commonly reviewed before buying Ursodeoxycholic Acid 128-13-2?
For pharmaceutical API procurement, buyers commonly align on specification review, target market, batch or annual demand, packaging expectations, and the documentation package needed for the project.
Request a Quote
If your team already has a target application, estimated quantity, destination market, or documentation requirements, send those details so the commercial response can be prepared more efficiently.